Steven Alvianto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Steven Alvianto has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Nicolas Daniel Widjanarko
School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia
5 shared publications Nicolas Daniel Widjanarko
4 shared publications- Stevan Kristian Lionardi
Faculty of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia
3 shared publications - Archie Fontana Iskandar
Cimacan General Regional Hospital, Cianjur, West Java, Indonesia
2 shared publications - Fransiskus Xaverius Rinaldi
School of Medicine and Health Science, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia
2 shared publications Johannes Cansius Prihadi
Department of Surgery, Sub Urology, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia
2 shared publications
Latest Publications
- Open Access
- 5 September 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (4) , 81-96
Comparative Efficacy and Safety of Interleukin-23 and Interleukin-12/23 Inhibitors in the Induction and Maintenance Phases of Crohn’s Disease: A Systematic Review and Network Meta-Analysis
Aim. To compare the efficacy and safety of interleukin (IL)-23 and IL-12/23 inhibitors during the induction and maintenance phases of Crohn’s disease using a Bayesian network meta-analysis. Materials and methods. Randomized controlled trials (RCTs) comparing guselkumab (GUS), risankizumab (RIS), ustekinumab (UST), mirikizumab (MIR), briakinumab (BRI), brazikumab (BRA), apilimod mesylate (API) and placebo (PBO) were analyzed. Outcomes included clinical and endoscopic remission/response, adverse events (AEs), and serious adverse events (SAEs). Bayesian random-effects models were used to estimate pooled odds ratios (ORs) with 95 % credible intervals (CrIs). Treatment rankings were determined using the surface under the cumulative ranking curve (SUCRA). Results. Twenty-one RCTs were included. During the induction phase, GUS ranked highest for clinical remission and clinical response, followed by RIS, MIR, and UST, with all agents demonstrating significant efficacy compared with PBO. RIS and MIR achieved significant improvements in endoscopic outcomes over PBO. GUS had the most favorable profile for AEs during induction, whereas RIS achieved greatest reduction in SAEs. During the maintenance phase, RIS was the only agent with demonstrated statistically significant efficacy for clinical remission compared with PBO. No agent achieved statistically significant endoscopic outcomes during maintenance; nevertheless, MIR and GUS ranked highest. Rates of AEs and SAEs were comparable across all active treatments. Conclusion. Guselkumab and risankizumab emerged as the most efficacious and safest IL-23 inhibitors for induction therapy, whereas risankizumab demonstrated the most sustained efficacy in maintenance phase.
- 5 September 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (4) , 81-96
Open AccessComparative Efficacy and Safety of Interleukin-23 and Interleukin-12/23 Inhibitors in the Induction and Maintenance Phases of Crohn’s Disease: A Systematic Review and Network Meta-Analysis
Aim. To compare the efficacy and safety of interleukin (IL)-23 and IL-12/23 inhibitors during the induction and maintenance phases of Crohn’s disease using a Bayesian network meta-analysis. Materials and methods. Randomized controlled trials (RCTs) comparing guselkumab (GUS), risankizumab (RIS), ustekinumab (UST), mirikizumab (MIR), briakinumab (BRI), brazikumab (BRA), apilimod mesylate (API) and placebo (PBO) were analyzed. Outcomes included clinical and endoscopic remission/response, adverse events (AEs), and serious adverse events (SAEs). Bayesian random-effects models were used to estimate pooled odds ratios (ORs) with 95 % credible intervals (CrIs). Treatment rankings were determined using the surface under the cumulative ranking curve (SUCRA). Results. Twenty-one RCTs were included. During the induction phase, GUS ranked highest for clinical remission and clinical response, followed by RIS, MIR, and UST, with all agents demonstrating significant efficacy compared with PBO. RIS and MIR achieved significant improvements in endoscopic outcomes over PBO. GUS had the most favorable profile for AEs during induction, whereas RIS achieved greatest reduction in SAEs. During the maintenance phase, RIS was the only agent with demonstrated statistically significant efficacy for clinical remission compared with PBO. No agent achieved statistically significant endoscopic outcomes during maintenance; nevertheless, MIR and GUS ranked highest. Rates of AEs and SAEs were comparable across all active treatments. Conclusion. Guselkumab and risankizumab emerged as the most efficacious and safest IL-23 inhibitors for induction therapy, whereas risankizumab demonstrated the most sustained efficacy in maintenance phase.
- Open Access
- 15 July 2026
- Published by ECO-Vector LLC (Publications) in Journal of Clinical Practice
- Vol. 17 (2) , 69-80
Association between prediabetes and sarcopenia risk: a systematic review and meta-analysis
BACKGROUND: Sarcopenia, the loss of muscle mass and strength, is a growing concern, especially in aging populations. Prediabetes, an intermediate state between normal glucose levels and diabetes, has been increasingly linked to muscle decline. AIM: to examine the association between prediabetes and sarcopenia risk. METHODS: A systematic search was conducted across databases including PubMed, ProQuest, Science Direct, Google Scholar, and the Cochrane Library to identify relevant studies on prediabetes and sarcopenia risk. Study quality was evaluated using the Newcastle-Ottawa Scale, and a meta-analysis was performed using Review Manager version 5.4. RESULTS: Five observational studies were included, with four undergoing quantitative synthesis. Results showed that individuals with prediabetes had a significantly higher likelihood of developing sarcopenia compared to those with normal glucose regulation (pooled OR 1.29, 95% CI 1.13–1.47; I2 = 7%). CONCLUSION: Prediabetes was associated with increased odds of sarcopenia. However, these findings should be interpreted with caution due to the small number of studies. Despite these limitations, the results highlight the importance of early detection and management of prediabetes to reduce the risk of sarcopenia.
- 15 July 2026
- Published by ECO-Vector LLC (Publications) in Journal of Clinical Practice
- Vol. 17 (2) , 69-80
Open AccessAssociation between prediabetes and sarcopenia risk: a systematic review and meta-analysis
BACKGROUND: Sarcopenia, the loss of muscle mass and strength, is a growing concern, especially in aging populations. Prediabetes, an intermediate state between normal glucose levels and diabetes, has been increasingly linked to muscle decline. AIM: to examine the association between prediabetes and sarcopenia risk. METHODS: A systematic search was conducted across databases including PubMed, ProQuest, Science Direct, Google Scholar, and the Cochrane Library to identify relevant studies on prediabetes and sarcopenia risk. Study quality was evaluated using the Newcastle-Ottawa Scale, and a meta-analysis was performed using Review Manager version 5.4. RESULTS: Five observational studies were included, with four undergoing quantitative synthesis. Results showed that individuals with prediabetes had a significantly higher likelihood of developing sarcopenia compared to those with normal glucose regulation (pooled OR 1.29, 95% CI 1.13–1.47; I2 = 7%). CONCLUSION: Prediabetes was associated with increased odds of sarcopenia. However, these findings should be interpreted with caution due to the small number of studies. Despite these limitations, the results highlight the importance of early detection and management of prediabetes to reduce the risk of sarcopenia.
- Open Access
- 30 June 2026
- Published by National Cancer Center Dharmais Cancer Hospital in Indonesian Journal of Cancer
- Vol. 20 (2) , 328-348
The Effect of Curcumin, Piperine, and Taurine Combination in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death and the sixth most diagnosed cancer. Curcumin (C) has anticancer effects toward HCC and may enhance the antitumor effects of certain traditional chemotherapeutic and molecular target drugs. Co administration with piperine (P) improves curcumin’s bioavailability, while taurine (T) also exhibits antitumor properties. This study aimed to assess the potential effects of the CPT combination on biochemical and immunological parameters in HCC patients. Following the PRISMA guidelines, a systematic review and meta-analysis were conducted using data from several databases, focusing on HCC and CPT studies. Review Manager 5.4 was used to perform the meta-analysis. Four studies involving 81 HCC patients met the inclusion criteria, with three included in the meta-analysis. Over three successive 30-day cycles of CPT treatment, significant reductions were observed in biochemical parameters including AST (SMD = 1.13, 95% CI: 0.29—1.97, p = 0.008), ALT (SMD = 0.33, 95% CI: 0.13—0.53, p = 0.001), and total bilirubin (SMD = 0.65, 95% CI: 0.45—0.85, p < 0.00001), while albumin levels showed no significant change (SMD = 0.00, 95% CI: -0.33—1.34, p = 0.98). Included studies indicated significant reductions in IL-10, CD25, miR-21, VEGF, CD4+CD25+%, and CD8+CD25+%, alongside increases in IFN-γ, CD4, CD8, IL-2, and IL-12 following CPT treatment. In conclusion, CPT combination therapy induced significant improvements in biochemical and immunological parameters across three treatment cycles, highlighting its potential as a promising natural therapeutic option for HCC management. Further research is necessary to validate these findings
- 30 June 2026
- Published by National Cancer Center Dharmais Cancer Hospital in Indonesian Journal of Cancer
- Vol. 20 (2) , 328-348
Open AccessThe Effect of Curcumin, Piperine, and Taurine Combination in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death and the sixth most diagnosed cancer. Curcumin (C) has anticancer effects toward HCC and may enhance the antitumor effects of certain traditional chemotherapeutic and molecular target drugs. Co administration with piperine (P) improves curcumin’s bioavailability, while taurine (T) also exhibits antitumor properties. This study aimed to assess the potential effects of the CPT combination on biochemical and immunological parameters in HCC patients. Following the PRISMA guidelines, a systematic review and meta-analysis were conducted using data from several databases, focusing on HCC and CPT studies. Review Manager 5.4 was used to perform the meta-analysis. Four studies involving 81 HCC patients met the inclusion criteria, with three included in the meta-analysis. Over three successive 30-day cycles of CPT treatment, significant reductions were observed in biochemical parameters including AST (SMD = 1.13, 95% CI: 0.29—1.97, p = 0.008), ALT (SMD = 0.33, 95% CI: 0.13—0.53, p = 0.001), and total bilirubin (SMD = 0.65, 95% CI: 0.45—0.85, p < 0.00001), while albumin levels showed no significant change (SMD = 0.00, 95% CI: -0.33—1.34, p = 0.98). Included studies indicated significant reductions in IL-10, CD25, miR-21, VEGF, CD4+CD25+%, and CD8+CD25+%, alongside increases in IFN-γ, CD4, CD8, IL-2, and IL-12 following CPT treatment. In conclusion, CPT combination therapy induced significant improvements in biochemical and immunological parameters across three treatment cycles, highlighting its potential as a promising natural therapeutic option for HCC management. Further research is necessary to validate these findings
- Open Access
- 15 October 2025
- Published by Springer Nature in Egyptian Liver Journal
- Vol. 15 (1) , 1-18
Preclinical and clinical evidence of xanthine oxidase inhibitors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
Introduction: Hyperuricemia is frequently reported to be associated with metabolic dysfunction-associated steatotic liver disease (MASLD). This study aimed to assess the effect of xanthine oxidase (XO) inhibitors on metabolic parameters in MASLD. Methods: A systematic search of databases including MEDLINE, ProQuest, Google Scholar, ScienceDirect, and Cochrane Library was conducted, focusing on preclinical and clinical studies relevant to XO inhibitors in MASLD. The Joanna Briggs Institute (JBI) critical appraisal tools were used for quality assessment in clinical studies, while the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE)’s risk-of-bias tool was used in preclinical studies. The meta-analysis was performed using Review Manager 5.4 to compute summary estimates for standardized mean differences (SMDs). Results: A total of eight studies were included in the review and seven in the meta-analysis. Significant differences in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and triglycerides (TG) were found in preclinical settings of MASLD animal models treated with XO inhibitors compared to controls. Meanwhile, in clinical settings, the serum uric acid (SUA) decreased significantly after treatment with febuxostat (SMD = 2.28, 95% CI: 0.76, 3.8, p = 0.003); however, there were no significant differences in liver enzymes, including AST and ALT (SMD = 0.05, 95% CI: −0.23, 0.32, p = 0.73). Both XO inhibitors had similar effects on liver enzymes and SUA in MASLD patients (SMD = 0.01, 95% CI: −0.40, 0.42, p = 0.96; SMD = −0.03, 95% CI: −0.39, 0.33, p = 0.87, respectively). Conclusions: While XO inhibitors have shown efficacy in preclinical models, clinical evidence is limited. Febuxostat and allopurinol have produced comparable effects on liver enzymes and serum uric acid (SUA), but differences in patient selection criteria reduce the comparability of findings.
- 15 October 2025
- Published by Springer Nature in Egyptian Liver Journal
- Vol. 15 (1) , 1-18
Open AccessPreclinical and clinical evidence of xanthine oxidase inhibitors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
Introduction: Hyperuricemia is frequently reported to be associated with metabolic dysfunction-associated steatotic liver disease (MASLD). This study aimed to assess the effect of xanthine oxidase (XO) inhibitors on metabolic parameters in MASLD. Methods: A systematic search of databases including MEDLINE, ProQuest, Google Scholar, ScienceDirect, and Cochrane Library was conducted, focusing on preclinical and clinical studies relevant to XO inhibitors in MASLD. The Joanna Briggs Institute (JBI) critical appraisal tools were used for quality assessment in clinical studies, while the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE)’s risk-of-bias tool was used in preclinical studies. The meta-analysis was performed using Review Manager 5.4 to compute summary estimates for standardized mean differences (SMDs). Results: A total of eight studies were included in the review and seven in the meta-analysis. Significant differences in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and triglycerides (TG) were found in preclinical settings of MASLD animal models treated with XO inhibitors compared to controls. Meanwhile, in clinical settings, the serum uric acid (SUA) decreased significantly after treatment with febuxostat (SMD = 2.28, 95% CI: 0.76, 3.8, p = 0.003); however, there were no significant differences in liver enzymes, including AST and ALT (SMD = 0.05, 95% CI: −0.23, 0.32, p = 0.73). Both XO inhibitors had similar effects on liver enzymes and SUA in MASLD patients (SMD = 0.01, 95% CI: −0.40, 0.42, p = 0.96; SMD = −0.03, 95% CI: −0.39, 0.33, p = 0.87, respectively). Conclusions: While XO inhibitors have shown efficacy in preclinical models, clinical evidence is limited. Febuxostat and allopurinol have produced comparable effects on liver enzymes and serum uric acid (SUA), but differences in patient selection criteria reduce the comparability of findings.
- 25 August 2025
- Published by SAGE Publications in Journal of Clinical Urology
- Vol. 19 (3) , 263-272
Fetuin-A (Alpha 2 HS Glycoprotein) as a predictor of urolithiasis: A systematic review and meta-analysis
Background: The global incidence of urolithiasis has doubled over the past four decades, potentially exacerbated by climate change. Fetuin-A (alpha-2-Heremans-Schmid glycoprotein) is a novel biomarker known for inhibiting calcification and is linked to chronic kidney disease and metabolic syndrome. This study aims to evaluate the association between fetuin-A levels and urolithiasis. Methods: A systematic search of MEDLINE, ScienceDirect, ProQuest, EBSCO, Google Scholar, and Cochrane Library was conducted for case-control studies comparing fetuin-A levels in urolithiasis patients versus controls. Study quality was assessed using the JBI Critical Appraisal tool. Meta-analysis was performed with RevMan and JASP. Results: Seven case-control studies comprising 395 urolithiasis patients and 282 controls (total n = 677) were included. Urinary fetuin-A levels were significantly lower in urolithiasis patients (SMD = -2.24, 95% CI: -4.24 to -0.23, p = 0.029, I² = 98%). Six studies also reported a trend of reduced serum fetuin-A levels. Conclusions: Fetuin-A may serve as a potential predictive biomarker for urolithiasis, particularly in recurrent cases. Significant urinary differences and serum trends warrant further research to clarify its diagnostic and prognostic value. Level of evidence: Not applicable
- 25 August 2025
- Published by SAGE Publications in Journal of Clinical Urology
- Vol. 19 (3) , 263-272
Fetuin-A (Alpha 2 HS Glycoprotein) as a predictor of urolithiasis: A systematic review and meta-analysis
Background: The global incidence of urolithiasis has doubled over the past four decades, potentially exacerbated by climate change. Fetuin-A (alpha-2-Heremans-Schmid glycoprotein) is a novel biomarker known for inhibiting calcification and is linked to chronic kidney disease and metabolic syndrome. This study aims to evaluate the association between fetuin-A levels and urolithiasis. Methods: A systematic search of MEDLINE, ScienceDirect, ProQuest, EBSCO, Google Scholar, and Cochrane Library was conducted for case-control studies comparing fetuin-A levels in urolithiasis patients versus controls. Study quality was assessed using the JBI Critical Appraisal tool. Meta-analysis was performed with RevMan and JASP. Results: Seven case-control studies comprising 395 urolithiasis patients and 282 controls (total n = 677) were included. Urinary fetuin-A levels were significantly lower in urolithiasis patients (SMD = -2.24, 95% CI: -4.24 to -0.23, p = 0.029, I² = 98%). Six studies also reported a trend of reduced serum fetuin-A levels. Conclusions: Fetuin-A may serve as a potential predictive biomarker for urolithiasis, particularly in recurrent cases. Significant urinary differences and serum trends warrant further research to clarify its diagnostic and prognostic value. Level of evidence: Not applicable
- Open Access
- 15 August 2025
- Published by The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy in The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy
- Vol. 26 (2) , 130-142
Probiotics for Preventing Relapse in Ulcerative Colitis: A Systematic Review and Bayesian Network Meta-Analysis
Background: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by periods of relapse and remission. Preventing relapse is critical to improving long-term outcomes. This study aimed to compare the efficacy of probiotics, 5-aminosalicylic acid (5-ASA), probiotics combined with 5-ASA, and placebo in preventing relapse in UC.Methods: A comprehensive search from PubMed, Cochrane Library, MEDLINE, ProQuest, ScienceDirect, Clinical Trials. gov and Google Scholar databases were conducted. The primary outcome was clinical relapse. A Bayesian random-effects model calculated pooled odds ratios (ORs) with 95% CIs and treatment ranks were assessed using the surface under the cumulative ranking curve (SUCRA).Results: Of total 552 initial papers, 37 extracted, and 26 were removed due to exclusion criteria. Eleven RCTs involving 1,099 participants were eventually included for analysis. Probiotics combined with 5-ASA had the highest efficacy (OR = 0.23, 95% CI: 0.027–1.09; SUCRA = 71.43), followed by 5-ASA alone (OR = 0.25, 95% CI: 0.035–0.95; SUCRA = 66.90) and probiotics alone (OR = 0.275, 95% CI: 0.059–0.724; SUCRA = 59.69). Placebo ranked lowest (SUCRA = 1.98). The most commonly used probiotics included E. coli Nissle 1917, Lactobacillus GG, and Bifidobacterium species. The most frequently used 5-ASA preparation was mesalazine. Interventions were generally well-tolerated, with no significant adverse events reported. Conclusion: With the Bayesian NMA, Probiotics plus 5-ASA demonstrates the highest efficacy in preventing relapses in UC. Further research is needed to standardize probiotic regimens and to assess long-term outcomes with the combination approach.
- 15 August 2025
- Published by The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy in The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy
- Vol. 26 (2) , 130-142
Open AccessProbiotics for Preventing Relapse in Ulcerative Colitis: A Systematic Review and Bayesian Network Meta-Analysis
Background: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by periods of relapse and remission. Preventing relapse is critical to improving long-term outcomes. This study aimed to compare the efficacy of probiotics, 5-aminosalicylic acid (5-ASA), probiotics combined with 5-ASA, and placebo in preventing relapse in UC.Methods: A comprehensive search from PubMed, Cochrane Library, MEDLINE, ProQuest, ScienceDirect, Clinical Trials. gov and Google Scholar databases were conducted. The primary outcome was clinical relapse. A Bayesian random-effects model calculated pooled odds ratios (ORs) with 95% CIs and treatment ranks were assessed using the surface under the cumulative ranking curve (SUCRA).Results: Of total 552 initial papers, 37 extracted, and 26 were removed due to exclusion criteria. Eleven RCTs involving 1,099 participants were eventually included for analysis. Probiotics combined with 5-ASA had the highest efficacy (OR = 0.23, 95% CI: 0.027–1.09; SUCRA = 71.43), followed by 5-ASA alone (OR = 0.25, 95% CI: 0.035–0.95; SUCRA = 66.90) and probiotics alone (OR = 0.275, 95% CI: 0.059–0.724; SUCRA = 59.69). Placebo ranked lowest (SUCRA = 1.98). The most commonly used probiotics included E. coli Nissle 1917, Lactobacillus GG, and Bifidobacterium species. The most frequently used 5-ASA preparation was mesalazine. Interventions were generally well-tolerated, with no significant adverse events reported. Conclusion: With the Bayesian NMA, Probiotics plus 5-ASA demonstrates the highest efficacy in preventing relapses in UC. Further research is needed to standardize probiotic regimens and to assess long-term outcomes with the combination approach.
- Open Access
- 15 July 2025
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 59 (4) , 235-248
AMACR is a highly sensitive and specific immunohistochemical marker for diagnosing prostate cancer on biopsy: a systematic review and meta-analysis
Background: Alpha-methylacyl-CoA racemase (AMACR) is the preferred biomarker for distinguishing malignant from benign glands in prostate biopsies, showing high sensitivity and specificity for prostate cancer. A meta-analysis of immunohistochemistry (IHC) for AMACR is essential to further assess its diagnostic accuracy across diverse sample sources. Methods: A systematic search of databases including MEDLINE, ScienceDirect, ProQuest, Google Scholar, and the Cochrane Library was performed, focusing on studies of AMACR to diagnose prostate cancer, particularly in biopsy samples analyzed through IHC over the last 20 years. Quality of studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 tool, followed by a meta-analysis of regions and subgroups to calculate summary estimates of diagnostic test accuracy. Results: In the final analysis, 37 studies, with a pooled size of 5,898 samples, were included from the examination of 94 full-text papers. Among them, 27 studies with similar sample sources and testing methodologies underwent meta-analysis, yielding a combined sensitivity estimate of 0.90 (95% confidence interval [CI], 0.86 to 0.93) and specificity of 0.91 (95% CI, 0.83 to 0.95), both with significant heterogeneity (p < .01). The region beneath the hierarchical summary receiver operating characteristic curve was 0.95 (95% CI, 0.93 to 0.97), positive likelihood ratio was 9.6 (95% CI, 5.3 to 17.4), negative likelihood ratio was 0.11 (95% CI, 0.08 to 0.15), and diagnostic odds ratio was 88 (95% CI, 42 to 181). Conclusions: Our meta-analysis findings substantiate AMACR as a highly accurate tool for diagnosing prostate cancer, specifically in biopsy samples, via immunohistochemical staining. Further studies involving diverse samples are needed to enhance our understanding of the AMACR diagnostic accuracy in a range of clinical settings.
- 15 July 2025
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 59 (4) , 235-248
Open AccessAMACR is a highly sensitive and specific immunohistochemical marker for diagnosing prostate cancer on biopsy: a systematic review and meta-analysis
Background: Alpha-methylacyl-CoA racemase (AMACR) is the preferred biomarker for distinguishing malignant from benign glands in prostate biopsies, showing high sensitivity and specificity for prostate cancer. A meta-analysis of immunohistochemistry (IHC) for AMACR is essential to further assess its diagnostic accuracy across diverse sample sources. Methods: A systematic search of databases including MEDLINE, ScienceDirect, ProQuest, Google Scholar, and the Cochrane Library was performed, focusing on studies of AMACR to diagnose prostate cancer, particularly in biopsy samples analyzed through IHC over the last 20 years. Quality of studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 tool, followed by a meta-analysis of regions and subgroups to calculate summary estimates of diagnostic test accuracy. Results: In the final analysis, 37 studies, with a pooled size of 5,898 samples, were included from the examination of 94 full-text papers. Among them, 27 studies with similar sample sources and testing methodologies underwent meta-analysis, yielding a combined sensitivity estimate of 0.90 (95% confidence interval [CI], 0.86 to 0.93) and specificity of 0.91 (95% CI, 0.83 to 0.95), both with significant heterogeneity (p < .01). The region beneath the hierarchical summary receiver operating characteristic curve was 0.95 (95% CI, 0.93 to 0.97), positive likelihood ratio was 9.6 (95% CI, 5.3 to 17.4), negative likelihood ratio was 0.11 (95% CI, 0.08 to 0.15), and diagnostic odds ratio was 88 (95% CI, 42 to 181). Conclusions: Our meta-analysis findings substantiate AMACR as a highly accurate tool for diagnosing prostate cancer, specifically in biopsy samples, via immunohistochemical staining. Further studies involving diverse samples are needed to enhance our understanding of the AMACR diagnostic accuracy in a range of clinical settings.
- Open Access
- 12 July 2025
- Published by Walter de Gruyter GmbH in Romanian Journal of Internal Medicine
- Vol. 63 (3) , 191-208
Myocardial performance index to assess cardiac function in spondyloarthritis: A systematic review and meta-analysis
Introduction: This study aimed to assess cardiac function using the Myocardial Performance Index (MPI) in spondyloarthritis (SpA) patients. Material and Methods: A comprehensive literature search was conducted in databases including Medline, ProQuest, Google Scholar, Scopus, and Cochrane Library, focusing on studies relevant to SpA and MPI from 1995 to 2023. The Newcastle Ottawa Scale (NOS) was employed to assess study quality, and meta-analysis computations were conducted utilizing Review Manager 5.4. Results: A total of 11 studies were included in this systematic review and meta-analysis. The spectrum of SpA covered in this review consisted of 1 study on undifferentiated spondyloarthritis (uSpA) and 10 studies on ankylosing spondylitis (AS). Various MPI assessment methods were utilized, including conventional echocardiography and tissue doppler imaging (TDI). In AS patients, both conventional MPI (cMPI) and tissue doppler MPI (tdMPI) values were significantly higher than those of healthy controls (MD= 0.05, 95% CI: 0.01–0.08, p-value=0.006 and MD=0.08, 95%CI: 0.06–0.10, p value<0.00001, respectively). In the uSpA study, there were no significant differences in MPI values between patients and controls with either cMPI or tdMPI. Conclusion: Significant differences in MPI values were observed between AS patients and healthy controls using both cMPI and tdMPI, suggesting that MPI may serve as a useful tool for early detection and management of cardiac dysfunction in AS patients. Further studies were required to validate these findings.
- 12 July 2025
- Published by Walter de Gruyter GmbH in Romanian Journal of Internal Medicine
- Vol. 63 (3) , 191-208
Open AccessMyocardial performance index to assess cardiac function in spondyloarthritis: A systematic review and meta-analysis
Introduction: This study aimed to assess cardiac function using the Myocardial Performance Index (MPI) in spondyloarthritis (SpA) patients. Material and Methods: A comprehensive literature search was conducted in databases including Medline, ProQuest, Google Scholar, Scopus, and Cochrane Library, focusing on studies relevant to SpA and MPI from 1995 to 2023. The Newcastle Ottawa Scale (NOS) was employed to assess study quality, and meta-analysis computations were conducted utilizing Review Manager 5.4. Results: A total of 11 studies were included in this systematic review and meta-analysis. The spectrum of SpA covered in this review consisted of 1 study on undifferentiated spondyloarthritis (uSpA) and 10 studies on ankylosing spondylitis (AS). Various MPI assessment methods were utilized, including conventional echocardiography and tissue doppler imaging (TDI). In AS patients, both conventional MPI (cMPI) and tissue doppler MPI (tdMPI) values were significantly higher than those of healthy controls (MD= 0.05, 95% CI: 0.01–0.08, p-value=0.006 and MD=0.08, 95%CI: 0.06–0.10, p value<0.00001, respectively). In the uSpA study, there were no significant differences in MPI values between patients and controls with either cMPI or tdMPI. Conclusion: Significant differences in MPI values were observed between AS patients and healthy controls using both cMPI and tdMPI, suggesting that MPI may serve as a useful tool for early detection and management of cardiac dysfunction in AS patients. Further studies were required to validate these findings.
- 3 July 2025
- Published by Taylor & Francis in International Journal of Sexual Health
- Vol. 37 (3) , 382-410
Male Responses to Female Partners with Genitopelvic Pain/Penetration Disorder: A Systematic Review of Biopsychological Impacts and Coping Strategies
Healthy romantic relationships involve emotional and physical connections as well as sexual fulfillment (World Health Organization, 2017). However, attaining intimacy can be challenging (Banaei et ...
- 3 July 2025
- Published by Taylor & Francis in International Journal of Sexual Health
- Vol. 37 (3) , 382-410
Male Responses to Female Partners with Genitopelvic Pain/Penetration Disorder: A Systematic Review of Biopsychological Impacts and Coping Strategies
Healthy romantic relationships involve emotional and physical connections as well as sexual fulfillment (World Health Organization, 2017). However, attaining intimacy can be challenging (Banaei et ...
- Open Access
- 30 April 2025
- Published by Maad Rayan Publishing Company in Middle East Journal of Digestive Diseases
- Vol. 17 (2) , 128-138
Chromogranin A as a Novel Biomarker of Irritable Bowel Syndrome in Adults: A Systematic Review and Meta-Analysis
Background: Irritable bowel syndrome (IBS) is a chronic condition characterized by recurring abdominal discomfort and irregular bowel movements. Currently, IBS diagnosis lacks specific radiological, biochemical, or endoscopic markers. Chromogranin A (CgA), a gastrointestinal protein, shows variation between patients with IBS and healthy controls. This study aimed to evaluate differences in CgA concentrations between these groups. Methods: This review was conducted in 2023 using the PRISMA 2020 guidelines. All observational research was retrieved from MEDLINE, EBSCO-Host, ScienceDirect, and ProQuest electronic databases using a predefined search strategy. Study quality was assessed using the Newcastle-Ottawa Scale (NOS), and meta-analysis was conducted using Review Manager (RevMan) 5.4. Results: Nine out of 14 studies eligible for meta-analysis revealed significantly higher CgA cell density (P=0.0001) in all patients with IBS compared with controls. This difference persisted across colon regions (left: P=0.04, right: P=0.0009) and duodenum (P<0.00001). Subgroup analysis found no significant disparity in CgA cell density between diarrhea and constipation-predominant IBS within the duodenum or colon. Conclusion: CgA cell density showed trends toward IBS compared with control groups, with significant concentration differences found in the duodenum, left, and right colon. Therefore, current findings might offer a histopathological approach to confirm the IBS diagnosis.
- 30 April 2025
- Published by Maad Rayan Publishing Company in Middle East Journal of Digestive Diseases
- Vol. 17 (2) , 128-138
Open AccessChromogranin A as a Novel Biomarker of Irritable Bowel Syndrome in Adults: A Systematic Review and Meta-Analysis
Background: Irritable bowel syndrome (IBS) is a chronic condition characterized by recurring abdominal discomfort and irregular bowel movements. Currently, IBS diagnosis lacks specific radiological, biochemical, or endoscopic markers. Chromogranin A (CgA), a gastrointestinal protein, shows variation between patients with IBS and healthy controls. This study aimed to evaluate differences in CgA concentrations between these groups. Methods: This review was conducted in 2023 using the PRISMA 2020 guidelines. All observational research was retrieved from MEDLINE, EBSCO-Host, ScienceDirect, and ProQuest electronic databases using a predefined search strategy. Study quality was assessed using the Newcastle-Ottawa Scale (NOS), and meta-analysis was conducted using Review Manager (RevMan) 5.4. Results: Nine out of 14 studies eligible for meta-analysis revealed significantly higher CgA cell density (P=0.0001) in all patients with IBS compared with controls. This difference persisted across colon regions (left: P=0.04, right: P=0.0009) and duodenum (P<0.00001). Subgroup analysis found no significant disparity in CgA cell density between diarrhea and constipation-predominant IBS within the duodenum or colon. Conclusion: CgA cell density showed trends toward IBS compared with control groups, with significant concentration differences found in the duodenum, left, and right colon. Therefore, current findings might offer a histopathological approach to confirm the IBS diagnosis.